- World rank, all time
- #36,040 of 42,892
- Rank in India
- #1,737 of 2,075
- Research works
- 141 ▲ 144% vs 2013–17
- Citations
- 1.4k 9.6 per fractional work
- Top-10% rate
- 9.7% record average 16.5%
- Open access
- 54% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 9.7×. Every wedge is a field page.
- Pharmacology, Toxicology and Pharmaceutics 9.7×
- Immunology and Microbiology 5.4×
- Decision Sciences 3.7×
- Medicine 2.8×
- Chemistry 2.6×
- Nursing 2.4×
- Biochemistry, Genetics and Molecular Biology 2.2×
- Neuroscience 1.2×
- Materials Science 0.8×
- Psychology 0.7×
- Mathematics 0.6×
- Business, Management and Accounting 0.5×
- Chemical Engineering 0.5×
- Economics, Econometrics and Finance 0.5×
- Computer Science 0.2×
- Environmental Science 0.2×
- Engineering 0.1×
- Health Professions 0.1×
- Agricultural and Biological Sciences 0.1×
Who are the top researchers at Intas Pharmaceuticals (India)?
Ranked on the composite score, Ronak Patel lead among researchers whose main affiliation is Intas Pharmaceuticals (India).
- 1 Ronak Patel India · #1,315,182 worldwide 20 citations · 19 works
Which keywords describe research at Intas Pharmaceuticals (India)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Monoclonal Antibodies, Biopharmaceuticals, Immunogenicity, Epidemiology, Clinical Outcomes, Cardiovascular Disease, Bioanalytical Methods and Biosimilars.
- Probiotics
- Chemotherapy-Induced Peripheral Neuropathy
- Pharmaceutical Analysis
- Green Analytical Chemistry
- Pharmacokinetics
- Insulin Resistance
- Health Services
- Glycosylation
- Diabetes
- Recombinant Proteins
- Gene Therapy
- Bayesian Networks
- SARS-CoV-2
- Global Burden
- Biosimilars
- Depression
- Clinical Trials
- Inflammation
- Immunogenicity
- Monoclonal Antibodies
- Epidemiology
- Biopharmaceuticals
- Cardiovascular Disease
- Clinical Outcomes
- Chemotherapy
- Bioanalytical Methods
- Therapeutic Antibodies
- Prophylaxis
- Stability
- Fault Tree Analysis
- Protein Aggregation
- ACE2 Receptor
- Drug Delivery
- Breast Cancer
- Heart Failure
- Metastatic Breast Cancer
- Thrombosis
- Monoclonal Antibody
- Antifungal Therapy
- Microbiota
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology5▲ 2.3×17 topics
- Monoclonal Antibodies4▲ 84×3 topics
- Biopharmaceuticals3▲ 130×2 topics
- Immunogenicity3▲ 155×2 topics
- Cardiovascular Disease3▲ 4.6×8 topics
- Inflammation2▲ 2.4×10 topics
- Clinical Outcomes2▲ 21×2 topics
- Clinical Trials2▲ 6.2×11 topics
- Chemotherapy2▲ 5.7×9 topics
- Depression2▲ 4.5×5 topics
- Bioanalytical Methods2▲ 189×1 topic
- Biosimilars2▲ 189×1 topic
- Therapeutic Antibodies2▲ 54×2 topics
- Global Burden2▲ 6.2×4 topics
- Prophylaxis2▲ 25×2 topics
- SARS-CoV-22▲ 9.6×4 topics
- Stability2▲ 13×2 topics
- Bayesian Networks2▲ 33×1 topic
- Fault Tree Analysis2▲ 60×1 topic
- Gene Therapy2▲ 16×4 topics
- Protein Aggregation2▲ 56×1 topic
- Recombinant Proteins2▲ 93×1 topic
- ACE2 Receptor1▲ 11×3 topics
- Diabetes1▲ 5.5×3 topics
- Drug Delivery1▲ 4.9×5 topics
- Glycosylation1▲ 23×3 topics
- Breast Cancer1▲ 9.7×4 topics
- Health Services1▲ 26×2 topics
- Heart Failure1▲ 5.7×5 topics
- Insulin Resistance1▲ 5.3×3 topics
- Metastatic Breast Cancer1▲ 41×2 topics
- Pharmacokinetics1▲ 9.2×2 topics
- Thrombosis1▲ 8.3×2 topics
- Green Analytical Chemistry1▲ 38×1 topic
- Monoclonal Antibody1▲ 42×2 topics
- Pharmaceutical Analysis1▲ 120×1 topic
- Antifungal Therapy1▲ 22×3 topics
- Chemotherapy-Induced Peripheral Neuropathy1▲ 63×1 topic
- Microbiota1▲ 9.5×2 topics
- Probiotics1▲ 8.7×2 topics
Which research topics does Intas Pharmaceuticals (India) publish most on?
By volume in 2022–2025: Biosimilars and Bioanalytical Methods, Risk and Safety Analysis, Protein purification and stability and Analytical Methods in Pharmaceuticals.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Biosimilars and Bioanalytical Methods Immunology 2 works
- 2 Risk and Safety Analysis Statistics, Probability and Uncertainty 2 works
- 3 Protein purification and stability Molecular Biology 2 works
- 4 Analytical Methods in Pharmaceuticals Analytical Chemistry 1 works
- 5 Mental Health Treatment and Access Social Psychology 1 works
- 6 Biotechnology and Related Fields Public Health, Environmental and Occupational Health 1 works
- 7 Cancer Treatment and Pharmacology Oncology 1 works
- 8 Gastrointestinal motility and disorders Gastroenterology 1 works
- 9 Hemophilia Treatment and Research Hematology 1 works
- 10 Drug Solubulity and Delivery Systems Pharmaceutical Science 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Intas Pharmaceuticals (India)'s research output changed?
Output in 2018–2022 was 144% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Ahmedabad
- Gujarat University
- Nirma University
- Physical Research Laboratory
- B.J. Medical College
- St Xavier’s College
- Indian Institute of Management Ahmedabad
- Government Dental College and Hospital
- National Institute of Pharmaceutical Education and Research - Ahmedabad
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.